Teresa S. Hyun

Fred Hutch Cancer Center — United States

Medicine · Health Sciences

18h-index1.2kcitations54works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(12), Chronic Myeloid Leukemia Treatments(9), Genetic Neurodegenerative Diseases(7), Chronic Lymphocytic Leukemia Research(7), Ubiquitin and proteasome pathways(6)

Publications54 total

Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy
Journal of Hematopathology·2024Open Access
Supplementary Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
2023Open Access
Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
2023Open Access
supplemental figure legend from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
2023Open Access
Supplementary Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
2023Open Access
Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
2023Open Access
supplemental figure legend from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
2023Open Access
Data from Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor
2023Open Access
Data from Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor
2023Open Access
Supplementary Table 1 from Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor
2023Open Access
Data from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
2023Open Access
Data from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
2023Open Access
Supplementary Figures 1-5, Tables 1-4 from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
2023Open Access
Supplementary Table 1 from Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor
2023Open Access
Supplementary Figures 1-5, Tables 1-4 from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
2023Open Access
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
UNC Libraries·2020· 2 citedOpen Access
KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation
Clinical Lymphoma Myeloma & Leukemia·2020· 8 cited
Disseminated adenovirus infection after autologous stem cell transplant
Transplant Infectious Disease·2019· 6 cited
Cutaneous Chronic GVHD: Sclerodermatous and Morpheic Variants
2019
The Basic Sequence of Injury in Acute Skin GVHD
2019
page 1 of 3Next →

Frequent Co-authors

Theodora S. Ross(17), Sarah V. Bradley(13), Howard M. Shulman(8), Mary E.D. Flowers(8), Peter C. Lucas(7), Sally Arai(7), Joseph Pidala(7), Iskra Pusic(7), Samantha Jaglowski(7), Nandita Khera(7), Jeanne Palmer(7), George L. Chen(7), Madan Jagasia(7), Sebastian Mayer(7), William A. Wood(7), Michael Green(7), Yoshihiro Inamoto(7), Barry E. Storer(7), Paul J. Martin(7), Stefanie Sarantopoulos(7)